The observed salutary effects of CDK4/6 inhibition on anti-tumor immunity could be the basis for a triple combination regimen associating a CDK4/6 inhibitor, an immune checkpoint inhibitor and a BRD4 inhibitor in colorectal cancer. The gene discussed is BRD4; the disease is neoplasm.